Search clinical trials for: Mitoxantrone Hydrochloride Liposome Injection

Total 18299 results

Children's Hospital of Soochow University

Recruiting

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML (GMCAII)

Acute Myeloid Leukemia | AML, Childhood

China
Wuhan Union Hospital, China
CSPC Pharmaceutical Group Limited

Recruiting

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

B-cell Acute Lymphoblastic Leukemia | B-cell Lymphoma Refractory

China
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

China
Second Affiliated Hospital of Soochow University
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Recurrent Metastatic Nasopharyngeal Carcinoma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder
Hui Zeng
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Relapsed or Refractory Multiple Myeloma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

Advanced Hepatocellular Carcinoma
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Advanced Gastric Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Withdrawn

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Advanced Malignant Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

Recurrent/Refractory Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

Advanced Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Advanced Recurrent or Metastatic Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Malignant Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection

Neoplasms
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Refractory Acute Myeloid Leukemia | Conditioning | Hematopoietic Stem Cell Transplantation | Relapse Leukemia
Peking Union Medical College Hospital

Not yet recruiting

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients (MA-PC-RWS-011)

Pancreatic Cancer

China
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Ruijin Hospital
Sun Yat-sen University; Shanghai Zhongshan Hospital; RenJi Hospital; Huashan Hospital and other collaborators

Recruiting

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia

China
Tianjin Medical University Cancer Institute and...
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
Affiliated Hospital of Nantong University

Recruiting

Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

Multiple Myeloma

China
Qiu Lugui

Recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Diffuse Large B-cell Lymphoma | Peripheral T Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Chi-GVM Regimen for the Treatment of R/R PTCL

Relapsed/Refractory Peripheral T-cell Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Breast Cancer

China
Luye Pharma Group Ltd.

Recruiting

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Relapsed Small Cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma
SCRI Development Innovations, LLC
Seagen Inc.

Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Breast Cancer

United States
Shanghai Pudong Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (easy laugh)

Breast Cancer

China
Sun Yat-sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Pediatric Solid Tumor

China
Jianfeng Zhou
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Baxter Healthcare Corporation

Not yet recruiting

Doxil/Caelyx BE Study

Multiple Myeloma | Ovarian Cancer | Metastatic Breast Cancer | AIDS-related Kaposi Sarcoma

Search clinical trials for: Mitoxantrone Hydrochloride Liposome Injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations